Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal C6 ceramide
- Development stage
- Preclinical
- Lead developer
- Penn State College of Medicine
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Liposomal C6 ceramide is a nanoliposomal formulation of the bioactive sphingolipid C6 ceramide (N-hexanoyl-D-erythro-sphingosine) designed to enhance the intracellular delivery and therapeutic efficacy of ceramide. Ceramide acts as a pro-apoptotic signaling molecule that is often downregulated in cancer cells. By delivering exogenous C6 ceramide, the compound inhibits the Akt/mTOR signaling pathway through the activation of protein phosphatase 1 (PP1) and induces caspase-dependent apoptosis. Developed primarily in the laboratory of Mark Kester, it has shown preclinical activity in various malignancies, including acute myelogenous leukemia (AML), melanoma, and solid tumors, often demonstrating synergy with other agents that modulate sphingolipid metabolism.
- Other names
- nanoliposomal C6-ceramideC6-ceramide nanoliposomesC-6-ceramide nanoliposomesC 6-ceramide nanoliposomesliposomal ceramide
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)CASP3 (Caspase-3)CASP9 (Caspase-9)GAPDH (Glyceraldehyde-3-phosphate dehydrogenase)αVβ3 (Integrin αVβ3)JNK (Mitogen-activated protein kinase kinase kinase family)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)PRKCZ (Protein kinase C zeta)PP1 (Protein phosphatase 1)PP2A (Protein phosphatase 2A)RK (Ribokinase)CASP (Caspase family)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on liposomal C6 ceramide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal C6 ceramide.